Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Summary

This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).

Timeline

Start

2023-01-31

Primary completion

2024-05-16

Completion

2024-05-16

Outcome

Outcome not reported

Stopped (Business): “The study was stopped due to a business decision.”

Drugs

Indications